Rhus verniciflua Stokes (RVS) and butein induce apoptosis of paclitaxel-resistant SKOV-3/PAX ovarian cancer cells through inhibition of AKT phosphorylation

BMC Complementary and Alternative Medicine

Volumn 16, Issue 1, 2016, Pages

  Choi, Hyeong Sim ^a   Kim, Min Kyoung ^a   Choi, Youn Kyung ^b,c   Shin, Yong Cheol ^c   Cho, Sung Gook ^d   Ko, Seong Gyu ^c  

^a Kyung Hee University Hospital   (South Korea)

^b Korea Research Institute of Ships and Ocean Engineering   (South Korea)

^c Kyung Hee University   (South Korea)

^d Chungju National University   (South Korea)

Author keywords

AKT; Apoptosis; Butein; Paclitaxel resistant ovarian cancer; Rhus verniciflua Stokes

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 7 AMINODACTINOMYCIN; BUTEIN; CASPASE 3; CASPASE 8; CASPASE 9; FISETIN; FLUORESCEIN ISOTHIOCYANATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PLANT EXTRACT; PROPIDIUM IODIDE; PROTEIN KINASE B; QUERCETIN; RHUS VERNICIFLUA EXTRACT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MTT ASSAY; OVARIAN CANCER CELL LINE; OVARY CANCER; PAX CELL LINE; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SKOV 3 CELL LINE; WESTERN BLOTTING; APOPTOSIS; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; OVARIAN NEOPLASMS; PHOSPHORYLATION; RHUS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CHALCONES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PHOSPHORYLATION; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS C-AKT; RHUS;

EID: 84964265142     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/s12906-016-1103-3     Document Type: Article

References (34)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5-29.
2. Torre L, Siegel RL, Jemal A. Global Cancer Facts & Figures. 3rd ed. Atlanta: American Cancer Society; 2015.
3. Li Y, Jiang Y, Wan Y, Zhang L, Tang W, Ma J, Wu S, Cheng W. Medroxyprogestogen enhances apoptosis of SKOV-3 cells via inhibition of the PI3K/Akt signaling pathway. J Biomed Res. 2013;27(1):43-50.
4. DiSaia PJ, Bloss JD. Treatment of ovarian cancer: new strategies. Gynecol Oncol. 2003;90(2 Pt 2):S24-32.
5. Lin YH, Chen BY, Lai WT, Wu SF, Guh JH, Cheng AL, Hsu LC. The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells. Naunyn Schmiedebergs Arch Pharmacol. 2015;388(1):19-31.
6. Borst P, Schinkel AH. P-glycoprotein ABCB1: a major player in drug handling by mammals. J Clin Invest. 2013;123(10):4131-3.
7. Sui H, Fan ZZ, Li Q. Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res. 2012;40(2):426-35.
8. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr. 1993;15:55-61.
9. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Med. 1997;48:353-74.
10. Ling X, Bernacki RJ, Brattain MG, Li F. Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem. 2004;279(15):15196-203.
11. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 2002;5(6):234-48.
12. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, et al. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem. 2002;277(36):33490-500.
13. Karam AK, Santiskulvong C, Fekete M, Zabih S, Eng C, Dorigo O. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken). 2010;67(8):535-44.
14. Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004;23(34):5853-7.
15. Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, et al. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary. Mol Cancer Res. 2015;13(4):795-806.
16. Choi W, Jung H, Kim K, Lee S, Yoon S, Park J, Kim S, Cheon S, Eo W, Lee S. Rhus verniciflua stokes against advanced cancer: a perspective from the Korean Integrative Cancer Center. J Biomed Biotechnol. 2012;2012:874276.
17. Hong MH, Kim JH, Lee SY, Go HY, Kim JH, Shin YC, Kim SH, Ko SG. Early antiallergic inflammatory effects of Rhus verniciflua Stokes on human mast cells. Phytother Res. 2010;24(2):288-94.
18. Park DK, Lee YG, Park HJ. Extract of Rhus verniciflua Bark Suppresses 2,4-Dinitrofluorobenzene-Induced Allergic Contact Dermatitis. Evid Based Complement Alternat Med. 2013;2013:879696.
19. Kim JH, Shin YC, Ko SG. Integrating traditional medicine into modern inflammatory diseases care: multitargeting by Rhus verniciflua Stokes. Mediators Inflamm. 2014;2014:154561.
20. Khan N, Adhami VM, Afaq F, Mukhtar H. Butein induces apoptosis and inhibits prostate tumor growth in vitro and in vivo. Antioxid Redox Signal. 2012;16(11):1195-204.
21. Na CH: Molecular mechanism by which Rhus Verniciflua Stokes induces apoptosis in SK-OV-3/PAC, chemoresistance ovarian cells. 2015:1-29. http://www.dcollection.net/handler/khu/000000164759
22. Shin SH, Koo KH, Bae JS, Cha SB, Kang IS, Kang MS, Kim HS, Heo HS, Park MS, Gil GH, et al. Single and 90-day repeated oral dose toxicity studies of fermented Rhus verniciflua stem bark extract in Sprague-Dawley rats. Food Chem Toxicol. 2013;55:617-26.
23. Byun JS, Han YH, Hong SJ, Hwang SM, Kwon YS, Lee HJ, Kim SS, Kim MJ, Chun W. Bark Constituents from Mushroom-detoxified Rhus verniciflua Suppress Kainic Acid-induced Neuronal Cell Death in Mouse Hippocampus. Korean J Physiol Pharmacol. 2010;14(5):279-83.
24. Kang KA, Piao MJ, Madduma Hewage SR, Ryu YS, Oh MC, Kwon TK, Chae S, Hyun JW. Fisetin induces apoptosis and endoplasmic reticulum stress in human non-small cell lung cancer through inhibition of the MAPK signaling pathway. Tumour Biol 2016; pp 1-10. DOI 10.1007/s13277-016-4864-x
25. Ren MX, Deng XH, Ai F, Yuan GY, Song HY. Effect of quercetin on the proliferation of the human ovarian cancer cell line SKOV-3. Exp Ther Med. 2015;10(2):579-83.
26. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13(22):2905-27.
27. Urban BC, Collard TJ, Eagle CJ, Southern SL, Greenhough A, Hamdollah-Zadeh M, Ghosh A, Poulsom R. BCL-3 expression promotes colorectal tumorigenesis through activation of AKT signalling. 2015. DOI 10.1136/gutjnl-2014-308270
28. Falasca M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des. 2010;16(12):1410-6.
29. Zhang W, Cai J, Chen S, Zheng X, Hu S, Dong W, Lu J, Xing J, Dong Y. Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway. Mol Med Rep. 2015;12(1):1506-14.
30. Kim JH, Go HY, Jin DH, Kim HP, Hong MH, Chung WY, Park JH, Jang JB, Jung H, Shin YC, et al. Inhibition of the PI3K-Akt/PKB survival pathway enhanced an ethanol extract of Rhus verniciflua Stokes-induced apoptosis via a mitochondrial pathway in AGS gastric cancer cell lines. Cancer Lett. 2008;265(2):197-205.
31. Jung CH, Kim JH, Kim JH, Chung JH, Choi HS, Seo JB, Shin YC, Kim SH, Ko SG. Anti-inflammatory effect of Rhus verniviflua Stokes by suppression of iNOS-mediated Akt and ERK pathways: in-vitro and in-vivo studies. J Pharm Pharmacol. 2011;63(5):679-87.
32. Bai X, Ma Y, Zhang G. Butein suppresses cervical cancer growth through the PI3K/AKT/mTOR pathway. Oncol Rep. 2015;33(6):3085-92.
33. Song NJ, Yoon HJ, Kim KH, Jung SR, Jang WS, Seo CR, Lee YM, Kweon DH, Hong JW, Lee JS, et al. Butein is a novel anti-adipogenic compound. J Lipid Res. 2013;54(5):1385-96.
34. Moon DO, Kim MO, Lee JD, Choi YH, Kim GY. Butein suppresses c-Myc-dependent transcription and Akt-dependent phosphorylation of hTERT in human leukemia cells. Cancer Lett. 2009;286(2):172-9.